MedTrace Logo

Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma

NCT03275376 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-03-16

No results posted yet for this study

Summary

Target therapy with sorafenib is the standard of treatment for advanced Hepatocellular carcinoma (HCC), but the patient survival time is still unsatisfactory. The aims of this study are to prove statins improve the tumor responses and overall survival for patients who receive sorafenib therapy for advanced HCC by a prospective randomized controlled study.

Conditions

  • Overall Survival
  • Tumor Responses

Interventions

DRUG

Atorvastatin 10mg

Atorvastatin or placebo will be administered according to randomized allocations.

DRUG

Placebo Oral Tablet

Atorvastatin or placebo will be administered according to randomized allocations.

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • Teng-Yu Lee, MD · Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-21
Primary Completion
2020-12-21
Completion
2021-03-13

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03275376 on ClinicalTrials.gov